Jiangsu Yangtze River Medical Technology Corp. headquartered in China Medical City, and established in August 2011, focusing on the professional research and development, production, and sales of mid-to-high-end medical devices.

   Over years of dedicated development, The company has accumulated extensive expertise in new product R&D, manufacturing, and production management. and has an outstanding scientific research team, enabling to undertake major scientific and technological projects and carry out independent technological innovation.

   The company has been honored with prestigious titles including National High-Tech Enterprise, Jiangsu Gazelle Enterprise, and National Outstanding Enterprise in Innovation and Entrepreneurship Competitions. Furthermore, has established a provincial-level Engineering Technology Research Center.

   covering a total area of nearly 15000 square meters includes Class 100,000 clean room,  CNC areas, and general administrative areas, which is in compliance with NMPA GMP regulatory requirements.

   In March 2022, a subsidiary was established in Sichuan, focusing on the research and development of Class II and Class III medical devices, covering key clinical fields such as urology, gastroenterology, dermatology, and neurology, and providing safe, precise, and efficient diagnostic and therapeutic support for patients and healthcare institutions.

   In July 2024, another subsidiary was founded in Suzhou, concentrating on post-procedure recovery for minimally invasive aesthetic treatments and injectable fillers. With a core focus on the regenerative medical materials and sodium hyaluronate, it aims to build a high-quality product portfolio to provide customers with comprehensive aesthetic medical solutions.

   In December 2025, Jiangsu Yangtze River Medical Technology Co., Ltd. acquired Jiangsu Poke Medical Technology Co., Ltd. Boke Medical is a high-tech enterprise specializing in needle-free drug delivery technology. Leveraging advanced microfluidic and fluid dynamics technologies, the company has developed the world-leading adjustable dual-stage pressure needle-free injection system, which enables precise and efficient subcutaneous drug delivery and provides customized drug delivery solutions for pharmaceutical research and development.

   Guided by the quality policy of "Pursuing Excellence in Quality, Stringently Controlling Product Risks, and Safeguarding Customer Value," we are committed to delivering premium products and services.setting a new benchmark for high-quality medical devices and fulfill our corporate mission: "Exploring Progress for Healthier Lives."